Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to ...
Lilly believes Kisunla can generate blockbuster sales. Kisunla is only the second drug on the market to treat Alzheimer's ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Most Americans 50 and older don't place much trust in health advice generated by artificial intelligence, a new survey finds.
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
The company's stock performance and future prospects hinge on several key factors, including the commercial success of Leqembi, pipeline developments, and its ability to overcome regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback